Cooperation SeekingCreative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced rituximab. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
Ibritumomab tiuxetan targets binding to the CD20 antigen found on the surface of normal and malignant B cells (instead of B cell precursors), thereby killing and killing B cells and some nearby cells through radiation of attached isotopes (mainly beta emission) . In addition, the antibody itself may trigger cell death through antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and apoptosis. These actions collectively eliminate B cells in the human body, thereby enabling lymphoid stem cells to form a new healthy B cell population.
All products and services are for Research Use Only. Do Not use in humans.
Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.